Bicycle Therapeutics plc filings document a clinical-stage pharmaceutical issuer whose Nasdaq-listed ADSs each represent one ordinary share. The company’s 8-K reports furnish quarterly and annual financial results, business highlights, program updates for nuzefatide pevedotin and the EphA2 pipeline, and leadership and board changes.
Proxy materials cover annual general meeting matters, director elections, executive compensation, equity awards, and shareholder voting procedures for the England and Wales company. The filings also identify the ordinary share and ADS registration structure, Nasdaq listing context, governance arrangements, and material-event disclosures tied to the company’s Bicycle technology and oncology pipeline.
Bicycle Therapeutics plc (BCYC) Chief Financial Officer Alethia Young reported sale of ordinary shares on 10/02/2025 to cover tax withholding and under a Rule 10b5-1 plan. The filing shows a sell-to-cover disposal of 217 shares at a weighted average price of $8.40 (sales ranged $8.37–$8.45) and a separate sale of 265 shares at $8.605. After the transactions the reporting person beneficially owned 44,704 ordinary shares (direct).
The report notes the 217-share sale was mandatory under the award agreement to satisfy statutory tax withholding on vested restricted stock units, while the 265-share sale followed a trading plan adopted on 04/03/2025. The filing is signed by an attorney-in-fact on 10/06/2025.
Bicycle Therapeutics PLC (BCYC) Chief Accounting Officer Travis Thompson reported two routine share sales tied to the vesting and settlement of restricted stock units. On 10/02/2025 he sold 221 ordinary shares at a weighted average price of $8.40 and on 10/03/2025 he sold 103 ordinary shares at a weighted average price of $8.41. The filings state these were "sell to cover" transactions required to meet statutory tax withholding for RSU vesting and were not discretionary sales. Following the transactions his direct beneficial ownership is shown as 31,197 ordinary shares.
Bicycle Therapeutics plc (BCYC) director Robert Charles Swanton reported a sale of 102 ordinary shares on 10/02/2025 at a price of $8.55 per share. The filing shows the sale was executed under a Rule 10b5-1 trading plan adopted on 10/14/2024, and the reporting person held 15,487 shares following the transaction. The form is a standard Section 16 filing reporting a non-derivative disposition by an insider; no options, grants, or other derivative transactions are reported.
Bicycle Therapeutics plc (BCYC) filed a Form 144 notice reporting a proposed sale of 102 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $872, intended for sale on 10/02/2025 on Nasdaq. The filing discloses that 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and were paid as equity compensation. The form also reports that the filer sold 411 shares on 07/02/2025 for gross proceeds of $3,058. The notice includes the statutory representation that the seller does not possess undisclosed material adverse information about the issuer.
Bicycle Therapeutics plc (BCYC) filed a Form 144 notifying a proposed sale of 543 shares of Common Stock through Stifel Nicolaus & Company Inc with an aggregate market value of $4,563. The filing lists the securities as to be sold on or about 10/02/2025 on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 (1,000 units) and 10/03/2025 (593 units). Prior reported sales by the same person in the past three months total 304 shares for gross proceeds of $2,191.
Bicycle Therapeutics plc (BCYC) filing a Form 144 notifies the SEC of a proposed sale of 486 shares of common stock with an aggregate market value of $3,447.00, scheduled for 10/02/2025 on Nasdaq. The filing shows those shares were acquired the same day as restricted stock units (RSUs) and paid as equity compensation, with an acquisition quantity of 750 RSU units dated 10/02/2025. The filer also reported a prior sale of 206 shares on 07/02/2025 for gross proceeds of $1,461.00. The company's outstanding share count listed in the form is 49,868,567, which places the proposed sale at a de minimis fraction of total shares outstanding.
Bicycle Therapeutics plc (BCYC) Form 144 notifies of a proposed sale of 2,264 shares of Common Stock through Stifel Nicolaus & Company Inc. on or about 10/02/2025, with an aggregate market value of $19,023. The filing lists total shares outstanding as 49,868,567, indicating the proposed sale is a small fraction of the company’s stock.
The securities were acquired as Restricted Stock Units from the issuer on 10/02/2025 (2,437 units) and 10/03/2025 (2,031 units) and paid as equity compensation. The filer (listed as Alistair Milnes at the address shown) previously sold 1,149 and 966 shares on 07/02/2025 and 07/03/2025, generating $8,148 and $7,184 respectively.
Bicycle Therapeutics plc director Herve Hoppenot received equity awards on September 8, 2025. The filing reports an award of 12,500 restricted share units (RSUs), each representing a contingent right to one ordinary share, and a grant of a stock option to purchase 25,000 ordinary shares at an exercise price of $7.16 per share. Both the RSUs and option vest in three equal annual installments on September 8, 2026, 2027 and 2028. Following the grants, Mr. Hoppenot beneficially owns 12,500 ordinary shares and has options covering 25,000 shares.
Roger D. Dansey, a director of Bicycle Therapeutics plc (BCYC), reported equity awards on a Form 4 filed for transactions dated 09/08/2025. The filing shows an award of 12,500 restricted share units (RSUs) and an option to purchase 25,000 ordinary shares at a $7.16 exercise price. Each RSU represents a contingent right to one ordinary share and the RSUs vest in three equal annual installments on 09/08/2026, 09/08/2027 and 09/08/2028. The option also vests in three equal annual installments on the same dates and expires on 09/08/2035. Ownership reported is direct for both awards.
Herve Hoppenot submitted an Initial Statement of Beneficial Ownership (Form 3) for Bicycle Therapeutics plc (BCYC) reporting the event date 09/08/2025. The filing identifies Mr. Hoppenot as a Director and states no securities are beneficially owned by him. The form is signed on behalf of the reporting person by an attorney-in-fact, Travis Thompson, dated 09/10/2025. The filing contains no equity holdings or derivative positions.